Recombinant human stem cell factor (rhSCF) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) are synergistic in vitro in stimulating the proliferation of hematopoietic progenitor cells and their precursors. We examined the in vivo synergy of rhSCF with rhG-CSF for stimulating hematopoiesis in vivo in baboons. Administration of low-dose (LD) rhSCF (25 pg/kg) alone did not stimulate changes in circulating WBCs. In comparison, administration of LD rhSCF in combination with rhG-CSF at 10 pg/kg or 100 pg/kg stimulated increases in circulating WBCs of multiple types up to twofold higher than was stimulated by administration of the same dose of rhG-CSF alone. When the dose of rhG-CSF is increased t o 250 pg/kg, the administration of LD rhSCF does not further increase the circulating WBC counts. Administration of LD rhSCF in combination with rhG-CSF also stimulated increased circulation of hematopoietic progenitors. LD rhSCF alone stimulated less of an increase in circulating progenitors, per milliliter of blood, than did administration of rhG-CSF alone at 100 pg/kg. Baboons administered LD rhSCF together with rhG-CSF at IO, 100, or 250 pg/kg had 3.5-t o 16-fold higher numbers per milliliter of blood of progenitors cells of multiple types, including colony-forming units granulocyte/macrophage (CFU-GM), burst-forming unit-erythroid (BFU-E), and colo-EMATOPOIETIC PROGENITORS and marrow-repopulating cells are present at very low frequencies in the blood of mice, dogs, baboons, and humans.'-* These cells appear in increased numbers in the circulation following perturbations of steady-state hematopoiesis such as recovery from the effects of chemotherapeutic agents'.'' and administration of specific hematopoietic growth factors.""4 ny-forming and burst-forming units-megakaryocyte (CFU-MK and BFU-MK) compared with animals given the same dose of rhG-CSF without rhSCF, regardless of the rhG-CSF dose. The increased circulation of progenitor cells stimulated by the combination of rhSCF plus rhG-CSF was not necessarily directly related to the increase in WBCs, as this effect on peripheral blood progenitors was observed even at an rhG-CSF dose of 250 pg/kg, where coadministration of LD rhSCF did not further increase WBC counts. Administration of very-low-dose rhSCF (2.5 pg/kg) with rhG-CSF, 10 pglkg, did not stimulate increases in circulating WBCs, but did increase the number of megakaryocyte progenitor cells in blood compared with rhG-CSF alone. LD rhSCF administered alone for 7 days before rhG-CSF did not result in increased levels of circulating WBCs or progenitors compared with rhG-CSF alone. Thus, the synergistic effects of rhSCF with rhG-CSF were both dose-and time-dependent. The doses of rhSCF used in these studies have been tolerated in vivo in humans. The data suggest that LD rhSCF may be useful clinically in conjunction with rhG-CSF t o further stimulate the circulation of progenitor cells that are useful for marrow reconstitution after transplantation.
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Administration of recombinant human granulocyte/macrophage colony-stimulating factor (rhGM-CSF) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) during the phase of marrow recovery after chemotherapy can further augment the circulation of hematopoietic progenitor cells.15"7 The effects of combinations of growth factors on trafficking of progenitor and marrow-repopulating cells have yet to be fully investigated."
Recombinant human stem cell factor (rhSCF; also known as mast cell growth factor, steel locus factor, and kit ligand), the ligand for the product of the c-kit proto-~ncogene,'~-~' has biological activity in stimulating mature and immature cells of multiple hematopoietic lineages both in vitro and in vivo. rhSCF enhances the in vitro proliferation of progenitor cells from human and baboon marrow in response to specific hematopoietic growth f a~t o r s .~~. ' toxicities, probably related to mast cell activation, were observed at doses of 25 and 50 pg/kg/d of rhSCF. In preclinical animal models, doses of 100 to 200 ygkg were needed to stimulated significant biological Based on the observations that rhSCF was synergistic with rhG-CSF, as well as other growth factors, in stimulating the in vitro proliferation of progenitor cells, and that recombinant rat SCF had in vivo synergy with rhG-CSF in stimulating circulation of WBCs in mice and rats, we hypothesized that lowdose (LD) rhSCF should enhance the biological response to rhG-CSF in baboons. In these studies, we present data that rhSCF, at doses that do not have significant in vivo activity when given alone, will dramatically enhance the biological response to both low-and high-dose rhG-CSF in vivo. Importantly, rhSCF in combination with rhG-CSF can stimulate a more than 10-fold increase in the numbers of circulating progenitor cells of multiple types compared with rhG-CSF alone, and the kinetics of trafficking of progenitor cells is different for the combination of rhSCF plus rhG-CSF compared with rhG-CSF alone.
MATERIALS AND METHODS

Animals.
Healthy juvenile baboons (Papio cynocephalus cynocephalus or P cynocephalus anubis) were housed at the University of Washington Regional Primate Research Center, under American Association for Accreditation of Laboratory Animal Care-approved conditions. Studies were conducted under Institutional Review Board-and Animal Care and Use Committee-approved protocols. All animals were provided with water, biscuits, and fruit ad libitum throughout the study. All procedures, including bone marrow biopsies and blood draws, were performed after animals had been anesthetized with a combination of ketamine-HCI (Aveco, Fort Dodge, IA) and Xylazine (Haver, Shawnee, KS). A total of 27 animals were studied as part of these experiments. All but five of the animals were included as part of two different study groups with a period of at least 4 months between studies when no growth factors were administered. One animal given rhSCF alone at 25 pg/kg/d had been reported in a previous publication.** Peripheral blood samples, 1 to 2 mL, for colony-forming cell (CFC) assays, analysis of expression of the CD34 antigen, serum levels of rhG-CSF and rhSCF, and detection of antibodies to rhG-CSF and rhSCF were collected in preservative-free heparin. One-milliliter to 2-mL blood samples also were collected in EDTA for complete blood cell counts (CBCs). Differential cell counts (2100 cells) on peripheral blood smears stained with Wright-Giemsa were determined for each CBC. In studies of animals administered rhG-CSF 10 pg/kg alone, rhG-CSF 10 pgkg plus rhSCF 25 pg/kg, and rhSCF 25 pgkg alone, bone marrow biopsies were obtained before treatment and on days 7, 14, and 21 of the study. Marrow biopsies were obtained from sites on the iliac crest, distal femur, proximal humerus, and proximal tibia using an 11-gauge Jamshidi biopsy needle. The marrow biopsy site was the same for each animal at each time point, and each site underwent only one biopsy. Marrow biopsies were fixed in either B-5 fixative or buffered formalin. Multiple sections from marrow core biopsies were stained with hernatolyxin and eosin, and periodic acid-Schiff. Slides were examined by the hematopathologist without prior knowledge of the treatment the animals had received. Sections from normal cellular baboon marrows had a cellularity of 50% to 60% (cell to fat ratio, -1 : 1).
Growth factors and schedules for in vivo administration. rhSCF (1.5 mg/mL) and rhG-CSF (Filgrastim, Amgen, Inc, Thousand Oaks, CA; 1.0 mg/mL) were produced in Escherichia coli as previously described, purified to more than 99% p~r i t y , '~ and used as the unmodified proteins. Purified material was stored at 4°C until used. In some experiments, the factors were diluted 1.5 or 1:lO with sterile 0.9% (wtlvol) saline immediately before administration to have a volume of material that could be easily measured for subcutaneous injection, ie, a volume greater than 0.1 mL.
Growth factors were administered daily by a single subcutaneous injection for each factor, with the volume of each injection being less than 1.2 n L per injection site. The injections were administered in the lateral aspect of the thigh or midline of the back, which had been shaved before the start of each study. In all studies, the growth factors were administered daily for 14 days, after which animals were observed for a further 14 days. Plasma was stored with each blood draw for subsequent analysis of growth factor concentrations and analysis for antibodies to recombinant human growth factors. All animals had measurable increases in plasma G-CSF and/or SCF levels during the 14 days of growth factor treatment. Approximately one third of animals (eight of 24) given rhG-CSF and approximately 13% (two of 15) of those given rhSCF developed low titers of antibodies against the specific growth factor that they had received that were detectable at more than a single time point during the course of the studies (ie, between days 12 and 28). Five animals had apparent antibodies to either G-CSF or SCF detectable on only day 21 or day 28, but not at any other time. In all but one animal the appearance of detectable low titers of antibodies to either rhG-CSF or rhSCF was not associated with a decrease in measurable growth factor levels in plasma are an apparent alteration in biological response (ie, decrease in WBC count). One animal did develop very high titers of antibodies both to rhG-CSF (>1:200) and to rhSCF (> 1:1,000) during a second study, and this was associated with a disappearance of detectable rhG-CSF and rhSCF in the plasma and a decrease in both WBCs and progenitors in blood to pretreatment values despite continued growth factor administration (data not shown). The numbers of animals in each study group are summarized in Table 1 .
Monoclonal antibodies and immunofluorescent staining. Monoclonal antibody 12-8 (CD34) and the isotype-matched control antibody H12C12 (antimouse Thy 1.2) were used to label peripheral blood and marrow cells, and were stained with phycoerythrin (PE)-conjugated goat anti-mouse IgM (mu-chain-specific) antisera (Cal- , gentamicin sulfate 100 pg/mL, and recombinant human growth factors interleukin (1L)-3 (100 ng/mL), GM-CSF (100 ng/mL), IL-6 (100 ng/mL), erythropoietin (Epo; 4 U/mL), and rhSCF (100 ng/ mL) (purified material supplied by Amgen, Thousand Oaks, CA). After the lower layer had gelled, cells in 0.5 mL Alpha Medium, 25%
FBS, 2% BSA, gentamicin, and 0.3% (wt/vol) agar were layered on top. Culture plates were placed in humidified polystyrene boxes in which the atmosphere was replaced by gassing with a 5% O?, 5% CO,, and 90% nitrogen gas mixture (Shumway Medical Supplies, Seattle, WA), after which the boxes were sealed with gas-impermeable tape (3M, St Paul, MN) and placed in a 37°C humidified incubator. At day 14 of culture, colony-forming units-granulocyte/macrophage (CFU-GM) and burst-forming units-erythroid (BFU-E) colonies were enumerated using an inverted microscope as previously described?"*' Two classes of baboon megakaryocyte (MKJ CFCs, including the more primitive burst forming unit-megakaryocyte (BFU-MK) and the more differentiated colony-forming unit-megakaryocyte (CFU-MK) were assayed from 1 .O X lo5 peripheral blood cells in a serumdepleted fibrin clot assay system as previously de~cribed."~~" rhSCF (1U0 nglmL) and rhIL-3 (100 ngimL) were used as sources of colonystimulating activity. The cultures were incubated for 21 days in 100% humidified, 5% CO, in air to quantitate both BFU-MK-and CFU-MK-derived colonies. After incubation, the fibrin clots were fixed in situ in a methanol acetone solution (1:3 vol/vol) for 30 minutes, washed with Dulbecco's phosphate-buffered saline (D-PBS), and air-dried.
Mouse-antihuman CD4la clone M148 monoclonal lgGl antibody (anti-CD4la; Biodesign International, Kennebunkport, ME) was For personal use only. on November 11, 2017. by guest www.bloodjournal.org From The 35-mm dishes were inverted and their base areas completely scanned at IOOX using a microscope with a reflected fluorescent light attachment. Both BFU-MK-and CFU-MK-derived colonies were identified by previously described riter ria.^^.^'
All cultures were performed in triplicate unless otherwise indicated. Data are reported as the mean ? SEM per 1 X lo5 peripheral blood buffy coat cells. To calculate the number of colony-forming cells per milliliter of blood, the following equation was used: colonies per milliliter of blood = (colonies per IO5 cells X total WBCs per milliliter b100d)lio~.
RESULTS
Effects of LD rhSCF in combination with rhG-CSF on circulating WBC counts. rhG-CSF administered to baboons at doses of 10, 100, and 250 pgkg/d (Table 1) elicited a dose-dependent leukocytosis (Fig 1) . Administration of rhSCF alone at a low dose of 25 pgkgld (LD rhSCF) did not stimulate a leukocytosis, consistent with our previous observations.28 Therefore, we asked if LD rhSCF administered with rhG-CSF would increase the WBC counts above those stimulated by rhG-CSF alone.
Administration of LD rhSCF plus rhG-CSF 100 pgkg stimulated increases in WBCs that were up to 1 S-fold higher compared with baboons given the same dose of rhG-CSF alone (Fig 2) . The increase in total WBC count was primarily a result of increases in neutrophils, but also reflected higher absolute monocyte and lymphocyte counts (Fig 2) . No consistent increases in circulating eosinophils or basophils were seen in animals treated with LD rhSCF alone or in combination with any of the doses of rhG-CSF studied (data not shown). Animals administered LD rhSCF plus 10 pgkg of rhG-CSF had total WBC counts up to twofold higher compared with animals administered 10 pgkg of rhG-CSF alone (Fig 3) . However, animals administered 250 pgkg rhG-CSF plus LD rhSCF did not develop WBC counts higher than those animals administered 250 pgkg of rhG-CSF alone (Fig 3) .
Since animals given LD rhSCF at the same time as rhG-CSF (10 and 100 pgkg) developed WBC counts higher than those of animals given rhG-CSF alone, we asked if administration of LD rhSCF for 7 days followed by 100 pg/ kg of rhG-CSF for 7 days would also stimulate increases in circulating WBCs compared with rhG-CSF alone. There was no change in the total WBC count during the first 7 days of LD rhSCF alone. The increase in WBCs observed during the following 7 days of rhG-CSF was not different from that observed in animals administered rhG-CSF alone at 100 pg/ kg for 7 days (data not shown). Thus, LD rhSCF did not "prime" for an enhanced leukocytosis in response to rhG-CSF. We also asked if the higher WBC counts in animals given LD rhSCF plus rhG-CSF was dependent on the dose of rhSCF. Animals administered 10 pgkg rhG-CSF plus rhSCF at 2.5 pgkg did not have a significant increase in WBC counts compared with animals given rhG-CSF at 10 pgkg alone (Fig 3) . Thus, the effects on peripheral blood WBCs of rhSCF administered in combination with rhG-CSF were dependent on the dose of rhSCF and rhG-CSF administered, as well as on the timing of factor administration.
Effects of LD rhSCF in combination with rhG-CSF on hematocrit and platelet counts. The hematocrits and platelet counts of animals administered LD rhSCF alone did not change (Figs 4 and 5) . Animals administered rhG-CSF at 100 and 250 pgkg alone developed lower hematocrits and platelet counts during the 14 days of growth factor administration compared with pretreatment values. Animals administered LD rhSCF plus rhG-CSF at 100 or 250 p e g developed transiently lower hematocrits and platelet counts compared with animals given the comparable dose of rhG-CSF alone (Figs 4 and 5) . Animals administered 10 p e g rhG-CSF alone or 10 pgkg rhG-CSF plus LD rhSCF did Effects of LD rhSCF on traficking of hematopoietic progenitor cells in the circulation. The frequency of hematopoietic CFCs (per lo5 peripheral blood buffy-coat cells) in blood, including CFU-GM, BFU-E, and MK-CFC, increased more than fivefold above pretreatment values by day 4 in baboons administered 100 pgkg of rhG-CSF alone (Fig 6) . Given the increase in WBCs, the maximum number of CFCs per milliliter of blood increased more than 20-fold above baseline. Animals administered LD rhSCF alone had slightly smaller increases in the frequencies of CFC in blood compared with animals given 100 pgkg of rhG-CSF alone. Since the WBC count was unchanged in these animals, the total CFC per milliliter of blood was increased at most threefold above pretreatment levels. In contrast, animals given both LD rhSCF and rhG-CSF (100 pgkg) had markedly larger increases in peripheral blood CFU-GM, BFU-E, and MK-CFC compared with animals given the same dose of rhG-CSF alone (Fig 6) , with the mean peak of CFC per lo5 blood cells being 3.6-fold higher and the maximum total CFC per milliliter of blood being at least 6.4-fold higher. Compared with pretreatment values, the total CFC per milliliter of blood was increased more than 300-fold in animals given both LD rhSCF and rhG-CSF, in contrast to a 50-fold increase in CFC per milliliter in animals given rhG-CSF alone.
G-CSF (1OO@kg)
In animals given 250 pgkg of rhG-CSF alone, the highest frequency of progenitor cells, Cm-GM and BFU-E, in the blood occurred on day 12, and was approximately twofold higher than the highest frequency of peripheral blood progenitor cells in animals given 100 pgkg of rhG-CSF alone, which occurred on day 4. Despite the fact that animals given both LD rhSCF and 250 pgkg of rhG-CSF did not have higher WBC counts, these animals had up to 3.5-fold more CFU-GM, BFU-E, and MK-CFC per milliliter of blood compared with animals given 250 pgkg rhG-CSF alone (Fig 7) . Animals given LD rhSCF plus 10 pgkg rhG-CSF had up to 8.5-fold more CFU-GM and BFU-E and 5.3-fold more MK-CFC per lo5 peripheral blood cells, and up to 16.4-fold higher total CFCs per milliliter of blood at the peak values compared with the peak values for animals given 10 pgkg rhG-CSF alone (Fig 7) . The effect of rhSCF in enhancing the circulation of CFCs was dose-dependent. Baboons administered rhG-CSF at 10 pgkg plus a 10-fold lower dose of rhSCF (2.5 pgikg) did not have higher numbers of CFU-GM or BFU-E in the blood compared with baboons administered rhG-CSF, 10 pg/kg, alone (data not shown). However, these animals did have increased numbers of MK-CFCs (5.2 2 1.0 CFU-MK and 1.1 2 0.3 BFU-MK per lo5 cells on day 12) compared with animals given the same dose of rhG-CSF (I .6 2 0.3 CFU-MK and 0 BFU-MK per lo5 cells on day 12). LD rhSCF administered for 7 days followed by 7 days of rhG-CSF at 100 pgkg did not stimulate higher numbers of CFCs in the blood compared with rhG-CSF alone at 100 pgkg (data not shown).
Circulation of CD34+ cells in response to administration of rhSCF in combination with rhG-CSF. The frequency of cells in blood expressing the CD34 antigen was determined for baboons treated with rhG-CSF and with the combination of rhG-CSF and rhSCF. During the period of growth factor administration, the frequency of detectable CD34+ cells in the circulation increased over pretreatment values for all animals, whether they were treated with rhG-CSF or the combination of rhSCF plus rhG-CSF. Two populations of cells with different fluorescent intensities were observed after staining blood cells from growth factor-treated animals with the anti-CD34 antibody 12.8 (Fig 8) . To determine which of these stained populations contained the detectable CFCs, we used fluorescence-activated cell sorting to isolate cells from these two populations from the blood of two animals receiving rhG-CSF and rhSCF on days 9 and 12 of growth factor administration ( Table 2 ). The population with the brightest staining for CD34 contained most of the detectable CFCs. Virtually all of these brightly staining CD34+ cells expressed high levels of HLA-DR (data not shown). Based on this finding, we analyzed flow cytometry data for expression of CD34 using gating on the brightest staining population to determine if there was any difference between animals receiving rhG-CSF alone or rhG-CSF plus rhSCF.
The frequency (per 5 X IO4 cells analyzed) of brightly staining CD34+ cells in blood was not different between animals given rhG-CSF alone or the combination of rhG-CSF and rhSCF. Similarly, there was not a discernible difference between animals administered different doses of rhG-CSF. As a result, when data were pooled, the frequency of brightly staining CD34+ cells was not predictive of the frequency of detectable CFCs in the sample. Changes in marrow cellularity and morphology in buboons administered rhG-CSF or rhG-CSF plus rhSCF. Bone marrow biopsies were obtained immediately before growth factor administration, on day 7 and 14 of treatment, and 7 days after the last dose of growth factor in animals administered rhG-CSF 10 pgkgld alone and rhG-CSF 10 pgkg/d plus LD rhSCF. Before treatment, the marrow cellularity (the proportion of marrow space occupied by hematopoietic cells) was similar in all animals, between 50% to 60%. By day 14 of growth factor treatment, the marrow cellularity was consistently higher in the three animals given 10 pgkg of rhG-CSF plus LD rhSCF (95%, loo%, 100%) compared with the three animals given 10 pgkg of rhG-CSF alone (75%, 80%, 85%). In addition, the marrows of ANDREWS ET AL animals administered both rhG-CSF and rhSCF contained multiple foci of very immature myeloid cells and a marked left shift compared with the marrows from animals administered rhG-CSF alone, which showed increases in more mature granulocytic elements (Fig 9) . Marrow biopsies from animals given LD rhSCF alone showed no changes in bone marrow cellularity or morphology.
Toxicities related to udministrution of rhG-CSF and rhSCF. There were no cutaneous reactions at the injection sites or at distal sites during the course of growth factor administration. There were no apparent changes in appetite or behavior during the course of growth factor administration, and no significant changes in body weight. Animals given 25 pgkg of rhSCF alone had no apparent adverse effects.
Animals given 100 pgkg and 250 pgkg, but not 1 0 pg/ kg, developed anemia and thrombocytopenia during the period of rhG-CSF administration. The higher the dose of rhG-CSF, the lower the nadir of hematocrit and platelets. The nadir for both hematocrit and platelets was lower for animals given LD rhSCF plus rhG-CSF compared with animals given rhG-CSF alone at the same dose. A portion of all animals studied were also examined for the development of enlarged lymph nodes, spleen, and liver. Palpable enlargement of the liver was not found in any of the animals. Enlarged spleens were palpable in one of three animals given 250 &kg rhG-CSF alone, one of three given 250 &kg rhG-CSF plus LD rhSCF, and three of six given 100 pgkg rhG-CSF plus LD rhSCF. None of the animals given rhG-CSF alone at 100 ,@kg (zero of three) and 10 pgkg (zero of three), and none had total WBCs of 1.07 x 108/mL of blood and total CFCs of 95,054 t 9,905/mL of blood. On day 9, A91308 had total WBCs of 1.10 x lo8/ mL and total CFCs of 24,937 2 1,276/rnL of blood. Animal F91065 had total WBCs of 1.60 x 108/mL and total CFCs of 70,752 -c 14,729/mL of blood on day 12, and had total WBCs of 1.39 x 108/mL and total CFCs of 39,909 rt 9,772/mL of blood on day 9 (see Fig 8) .
of the animals given rhG-CSF at 10 pgkg plus LD-rhSCF (zero of five) had enlarged spleens. A portion of animals in all study groups had mildly enlarged inguinal and axillary lymph nodes after 14 days of growth factor administration. Palpable splenomegaly and lymphadenopathy resolved within 1 week after growth factor administration was stopped.
One animal receiving rhG-CSF at 100 pg/kg/d plus rhSCF at 25 pg/kg/d developed a left-sided cerebral hemorrhage with hemiplegia on the 14th day of factor administration, requiring that the animal be euthanized. At that time, the W C count had increased to 217,80O/pL from 134,20O/pL the previous day. The platelet count at the time of the episode was 11O,OOO/pL. Necropsy showed a large focal hemorrhagic infarct in the right cerebral hemisphere. Areas of microscopic infarction were present in the liver, kidney, myocardium, and colon associated with neutrophilic infiltrates. Also noted was cortical and paracortical lymphoid hyperplasia in enlarged lymph nodes, depletion of lymphoid cells from the spleen and thymus, and accumulation of neutrophils in the alveolar walls in the lungs. These findings are similar to previously reported studies in nonhuman primates in which cerebral hemorrhage was associated with very high peripheral blood WBC counts stimulated by rhG-CSF alone."'
DISCUSSION
Certain hematopoietic growth-and differentiation-inducing factors have been shown to stimulate not only the increased production of mature hematopoietic elements in blood and marrow, but also the trafficking of progenitor cells into the The mechanism by which progenitor trafficking occurs is not known, although it is possible that altered expression andor function of cellular adhesion molecules has an important role. Papayannopoulou and Nakamoto showed that by blocking VLA-4 ligand binding in vivo, they could induce circulation of progenitor and that this effect of anti-VLA-4 antibodies could further enhance the circulation of progenitors stimulated by specific growth factors. Whether any growth factors can stimulate a true in vivo expansion or increase in the total number of progenitor cells or their precursors, or whether progenitors are simply redistributed within hematopoietic tissues, remains controver~i a l . @ *~~ Regardless, the ability of specific factors to stimulate the circulation of progenitors by themselves or to enhance the circulation of progenitors observed during the recovery from myelosuppressive chemotherapy have been used to collect these cells from the circulation for therapeutic purposes. The present studies demonstrate that in vivo administration of LD rhSCF (25 pgkg), a dose that by itself elicits little biological response, can enhance the leukocytosis and circulation of CD34' progenitor cells stimulated by rhG-CSF in baboons when both factors are given together, but not when they are administered sequentially. Nonetheless, the stimulation of progenitor cell trafficking was not directly related to the increases in WBCs, as at the highest dose of rhG-CSF studied, 250 pg/kg, the coadministration of rhSCF did not augment the W C count, but it did significantly increase the number of progenitor cells detectable in the matopoiesis in vivo.9.10.13,29,37.38
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From blood. Further, the addition of 2.5 pglkg of rhSCF to 10 pgl kg of rhG-CSF did not further increase the WBC count, but did increase megakaryocyte progenitors in the circulation.
The present study suggests that caution is indicated when interpreting data on the frequency of CD34' cells in the circulation in the absence of other functional assays. The frequency of CD34' cells identified by flow cytometry was not highly correlated with the frequency of progenitors detected by CFC assays. It remains to be determined if CD34' cells identified in the circulation may differ when stimulated by different growth factors.
The combination of SCF plus G-CSF, as well as G-CSF alone, can stimulate the circulation of marrow-repopulating cells in mice, dogs, and baboon^^'.^^ (Andrews RG, McNiece IK, Appelbaum FR, unpublished observations). More importantly, animals transplanted with blood cells collected after treatment with the combination G-CSF plus SCF have significantly more rapid recovery of platelet and neutrophil counts compared with animals transplanted with cells collected after treatment with rhG-CSF alone. Thus, the use of combinations of factors may be useful for stimulating the circulation of marrow-repopulating cells for clinical marrow transplantation. Finally, the death of one animal, associated with very high WBC counts, provides a cautionary note against raising WBC counts too high in clinical trials.
